Celgene in the news
Discovering innovative medicines
Tamtam found 20 recent articles about Celgene.
- U.S. Pancreatic Cancer Treatment Market Is Going to Boom |• Amgen • Celgene • Eli Lilly
The U.S. Pancreatic Cancer Treatment Market is expanding due to technological progress and shifting demands, with key players like Celgene driving growth.
- Celgene Defends Dismissal Of Cancer Drug Antitrust Suit
Bristol-Myers Squibb and its subsidiary Celgene Corp. are asking the Second Circuit to affirm the dismissal of an antitrust class action alleging fraudulent cancer drug patent acquisition.
- Bristol-Myers, Others Appeal Revlimid MDL To 3rd. Circ.
Pharmaceutical companies are appealing an antitrust multidistrict litigation concerning Celgene's cancer drug Revlimid.
- FDA Approval for REBLOZYL issued to CELGENE CORP
Alamere Labs' Beagle service monitors Celgene Corp. market activity, including the recent FDA approval of REBLOZYL, and provides real-time alerts on significant events.
- ANTITRUST—D.N.J.: Revlimid buyers’ pay-for-delay antitrust claims survive drugmakers’ motion to dismiss
A federal court allowed antitrust claims to proceed against Celgene and other drugmakers, alleging their 2015 settlement with Natco Pharma unlawfully delayed generic Revlimid entry and maintained high prices.
- Bristol-Myers, Natco And More Can't Ditch Cancer Drug MDL
A New Jersey federal judge refused to dismiss an antitrust multidistrict litigation concerning Celgene's cancer drug Revlimid, involving Bristol-Myers Squibb, Natco Pharma, and AbbVie.
- Celgene Fails to Fend Off Antitrust Claims in Pay-for-Delay Suit
A federal judge allowed an antitrust pay-for-delay lawsuit against Celgene Corp. and Natco Pharma Ltd. to proceed, concerning a settlement that allegedly delayed a generic blood cancer drug and kept prices high.
- Bristol-Myers, Natco And More Can't Ditch Cancer Drug MDL
A New Jersey federal judge did not dismiss an antitrust lawsuit against Bristol-Myers Squibb, Natco Pharma, and other companies regarding Celgene's cancer drug Revlimid, finding 'pay-for-delay' claims plausible.
- Celgene, Teva, others must face US antitrust claims over Revlimid, judge rules
A judge ruled that Celgene, Teva, and other companies must face US antitrust claims related to Revlimid.
- Celgene, Teva, others must face US antitrust claims over Revlimid, judge rules
A US judge ruled that Celgene, Teva, and other companies must face antitrust claims for allegedly monopolizing the Revlimid market.
- What Does Bristol Myers Squibb (BMY) Risk From The Revived $6.7 Billion Lawsuit?
A federal appeals court reinstated a US$6.7 billion lawsuit against Bristol Myers Squibb concerning its Celgene acquisition, alleging delayed FDA approvals to avoid payouts.
- Bristol Myers Squibb Faces Revival of USD 6.7 Billion Celgene Shareholders' Lawsuit
A US appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb over claims it delayed drug approvals to avoid payouts to former Celgene shareholders.
- Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
Bristol Myers Squibb secured accelerated FDA approval for Zenbexus, a multiple myeloma drug acquired from Celgene, demonstrating superior efficacy and projected to achieve over $1 billion in sales by 2031.
- Appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb over delayed drug approvals
Bristol Myers Squibb faces a revived $6.7 billion lawsuit regarding delayed drug approvals, brought by UMB Bank on behalf of former Celgene shareholders.
- US appeals court revives $6.7 billion lawsuit against Bristol Myers Squibb
A U.S. appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb concerning alleged delayed drug approvals affecting payments to former Celgene shareholders.
- Appeals court revives $6.7B lawsuit against Bristol Myers Squibb
Bristol Myers Squibb faces a revived $6.7 billion lawsuit from former Celgene shareholders after an appeals court overturned a lower court's dismissal.
- Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
Cigna-backed health plans are appealing a dismissed lawsuit against Bristol-Myers Squibb and Celgene, alleging fraudulent patent acquisition and sham litigation to protect a cancer drug from generic competition.
- Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
Cigna-backed health plans and pharmacies are seeking to revive a lawsuit against Bristol-Myers Squibb and Celgene, alleging fraudulent patent acquisition and sham litigation.
- Celgene Number of Employees 2026 | Employee Count & Headcount Data
Celgene Corp. has 1,379 employees globally as of March 2026, with its workforce declining by 17.5% since 2023 but maintaining positive employee sentiment.
- Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
Health plans and pharmacies are asking the Second Circuit to revive a class action alleging Bristol-Myers Squibb and Celgene used fraudulent patents and pay-for-delay tactics to monopolize the cancer drug Pomalyst.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Celgene?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies